Structure Therapeutics (GPCR) sees FMR disclose 15% ownership stake

Rhea-AI Filing Summary

Structure Therapeutics Inc received an amended Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 31,112,634 shares of its common stock, representing 15.0% of the class as of December 31, 2025.

FMR LLC has sole voting and dispositive power over these shares, while Abigail P. Johnson has sole dispositive power. The filers certify that the securities were acquired and are held on a passive basis, not to change or influence control of Structure Therapeutics.

Insights

Institutional ownership analyst

Large passive holder reports a 15% stake in Structure Therapeutics.

FMR LLC, a major institutional investor, reports beneficial ownership of 31,112,634 Structure Therapeutics common shares, equal to 15.0% of the class as of December 31, 2025. FMR has sole voting and dispositive power over this block.

Abigail P. Johnson is listed with sole dispositive power over the same number of shares, indicating control relationships within the ownership structure. The filing uses Schedule 13G certification language stating the position is not held for the purpose of changing or influencing control of the company.

The filing confirms Structure Therapeutics has a substantial passive institutional shareholder. Actual market impact depends on future portfolio decisions, but the 13G form and stated intent point to a non-activist, investment-oriented position rather than a control-driven stake.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

STRUCTURE THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

86366E106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 86366E106

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 31,112,634.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 31,112,634.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

31,112,634.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 86366E106

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 31,112,634.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

31,112,634.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: STRUCTURE THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 601 GATEWAY BLVD,SUITE 900,SOUTH SAN FRANCISCO,CA,USA,94080
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 86366E106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 31112634.00
(b)	Percent of class: 15.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 31112634.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of STRUCTURE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of STRUCTURE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	02/04/2026

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	02/04/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

What stake in Structure Therapeutics (GPCR) does FMR LLC report in this Schedule 13G/A?

FMR LLC reports beneficial ownership of 31,112,634 Structure Therapeutics common shares, equal to 15.0% of the class. The filing states this ownership as of December 31, 2025 and notes FMR holds sole voting and dispositive power over these shares.

How is Abigail P. Johnson involved in the Structure Therapeutics (GPCR) ownership reported here?

Abigail P. Johnson is listed as a reporting person with beneficial ownership of 31,112,634 shares. She is reported to have sole dispositive power over the same 15.0% stake in Structure Therapeutics common stock, aligning her economic interest with that of FMR LLC.

Is the FMR LLC 15% position in Structure Therapeutics (GPCR) an activist or passive stake?

The filing characterizes the 15.0% stake as passive. The certification explicitly states the securities were not acquired and are not held for the purpose of changing or influencing control of Structure Therapeutics, but instead reflect an investment position consistent with Schedule 13G rules.

What voting and dispositive powers does FMR LLC hold over its Structure Therapeutics (GPCR) shares?

FMR LLC reports sole voting and sole dispositive power over 31,112,634 shares of Structure Therapeutics common stock. The filing shows no shared voting or shared dispositive power, indicating centralized control of how this 15.0% stake is voted and potentially sold.

Do other investors share in the economic benefits of FMR’s Structure Therapeutics (GPCR) holdings?

The filing notes that one or more other persons have rights to dividends or sale proceeds from the common stock. However, it specifies that no single other person’s interest relates to more than five percent of Structure Therapeutics’ total outstanding common stock.

What is the event date for the ownership information in this Structure Therapeutics (GPCR) Schedule 13G/A?

The ownership information is stated as of December 31, 2025. That date is listed as the event requiring the filing, with the 31,112,634 shares and 15.0% class ownership figures tied specifically to that year-end reference point for Structure Therapeutics’ common stock.